Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb reports positive melanoma drug trial data

Bristol-Myers Squibb reports positive melanoma drug trial data

22nd March 2011

Bristol-Myers Squibb has announced positive results from a phase III drug trial of its new compound ipilimumab, which is being assessed as a metastatic melanoma treatment.

The clinical trial, known as study 024, was designed to assess the efficacy of the investigational therapy among patients with unresectable stage III or stage IV melanoma who had not received any prior treatment.

It was found that Bristol-Myers Squibb's compound combined with chemotherapy was able to deliver improvements in overall survival rates when compared to chemotherapy alone.

Full data from the study has been submitted for presentation by the company at the forthcoming annual meeting of the American Society of Clinical Oncology, which takes place in June 2011.

The information will help to support the firm's efforts to gain regulatory approval for ipilimumab in the US and other territories.

Earlier this month, Bristol-Myers Squibb agreed a new alliance that will see WuXi PharmaTech assist the company with its drug analysis efforts.ADNFCR-8000103-ID-800471134-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.